Adenocarcinoma of the prostate is the most common cancer in American men. It is estimated that in 1996 prostate cancer will account for over 40,000 deaths and 200,000 new cases will be reported. Despite the magnitude of the problem, our understanding of the molecular mechanisms involved in the initiation, progression, and metastasis of prostate cancer has been slow, largely due to the scarcity of adequate animal model systems that reproduce the spectrum of human prostatic disease. Therefore, we have undertaken the task of developing a transgenic mouse prostate cancer model to facilitate prostate cancer research.
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EXPERIMENTAL APPROACH
The first requirement in generating a transgenic mouse prostate cancer model was to identify and characterize a prostate-specific transgene expression system. To this end, various prostate-specific regulatory elements were evaluated for their ability to direct heterologous gene expression specifically and reproducibly to the prostate in transgenic mice. As a result of these studies, it was determined that a minimal 0.5-kb fragment of the rat probasin gene (PB) suitably directed developmentally and hormonally regulated transgene expression to the dorsolateral and ventral prostatic lobes of transgenic mice (7) . Having established a system to genetically manipulate gene expression specifically in the mouse prostate, the second requirement in generating the transgenic model was to assemble a recombinant construct that would induce neoplastic epithelial transformation as a consequence of heterologous gene expression. Because the most frequently observed genetic * Instructions to Authors Highlights of Contemporary Genetically Altered Models may be contributed or invited and is meant to acquaint toxicologic pathologists with important biological and morphological features of newly established transgenic, knock-out, and related genetically engineered animal models. Although these Highlights will be based upon previously published papers, submissions will be peer reviewed. Suggested format includes background; experimental approach; biological, clinical, and pathologic (lesions, pathogenesis, and histomorphology) features; applications and implications.
lesions associated with prostate cancer appeared to be the progressive loss of wild-type p53 (2, 5, 8, 10, 11, 14, 21 ) and Rb (11) (12) (13) 20) and no single dominant prostate cancer allele had yet been identified, it seemed logical to design a construct that would abrogate functional expression of the p53 and Rb tumor suppressor genes. Therefore, transgenic mice were generated with a PB-SV40 T antigen (Tag) construct because the SV40 large T antigen acts as an oncoprotein through interactions with both Rb (4) and p53 (15, 16) . Previous reports that the SV40 early-region tumor antigen had the ability to induce epithelial transformation in vivo (3, 9, 18, 19) and had been used successfully in transgenic mice to induce a transformed state in a variety of systems [for review, see Adams and Cory (1) ] provided additional support for this experimental design. Therefore, a PB-Tag transgene was used to generate the transgenic adenocarcinoma mouse prostate (TRAMP) model in the C57B1/6 inbred stain of mice.
BIOLOGICAL AND CLINICAL CHARACTERISTICS
Expression of the PB-Tag transgene is spatially restricted to the dorsolateral and ventral lobes of the male TRAMP mice (Fig. lA) . The temporal pattern of transgene expression correlates with sexual maturity and is hormonally regulated by androgens. At 12 wk of age, the structures within the prostate histologically resemble mild to severe hyperplasia and cribriform structures are readily apparent (Fig. 1B, C) . Immunohistochemistry and antibodies specific for the Tag oncoprotein reveal both individual immunoreactive cells with characteristics of normal epithelium and nests of obviously transformed cells. The observation that Tag expression precedes the transformed state supports the hypothesis that transgene expression is required but not sufficient for neoplastic transformation. It is likely that cells expressing the transgene are initially in a preneoplastic state, and other stochastic events are required to confer proliferative advantages and ultimately a malignant state. Severe hyperplasia and adenocarcinoma is observed by 18 wk of age in the TRAMP model. The epithelial origin of the tumors has been determined with antibodies specific for dorsolateral specific proteins (6) . At this time, invasion of epithelial cells into underlying smooth muscle FIG. Prostate cancer in a transgenic mouse. A) Gross pathology of prostate in a male TRAMP mouse at 27 wk of age. BL = urinary bladder; DLP = dorsolateral prostate; SV = seminal vesicle. B) Histologic section stained with hematoxylin and eosin shows mild to moderate hyperplasia of dorsolateral prostate. C) Histologic section stained with hematoxylin and eosin shows region of severe hyperplasia of dorsolateral prostate. Nc prevalence of apoptotic bodies. D) Histologic section stained with hematoxylin and eosin shows invasive adenocarcinoma and regions of mild severe hyperplasia. and stroma can be observed (Fig. ID) . By the time the mice are 24-30 wk of age, they will all display primary tumors. As one of the hallmarks of human prostate cancer is the progression to a metastatic disease, the pattern and incidence of metastatic spread in the TRAMP model is currently under investigation (J. Gingrich, manuscript in preparation). In contrast to mice carrying a C3(1)-Tag transgene (17) , no other primary pathologies are observed in the TRAMP mice. Female mice are normal and fertile.
APPLICATIONS AND IMPLICATIONS
The TRAMP model has a number of distinct advantages over existing models: (a) the transgene is specific for the epithelial cells of the prostate; (b) the tumor tissue histologically resembles the human disease (with severe hyperplasia and cribriform structures appearing as early as 10 wks); (c) the tumors arise with a short latency period and with 100% frequency; (d) the mice exhibit progressive stages of prostate cancer ranging from mild to severe prostatic hyperplasia with cribriform structures and focal adenocarcinoma and seminal vesicle invasion; (e) metastatic spread of the disease has been observed; (f) the mouse model can be used to follow the progression/multistage development of disease all within a 10-20-wk time period; (g) the mouse models exhibit less morbidity and mortality due to complications with other organs as seen in other transgenic models; and (h) the TRAMP model was generated in an inbred strain to facilitate immunological studies. It is anticipated that the establishment of the TRAMP mode] will facilitate many new avenues of research toward better prevention, diagnosis, and treatment of prostate cancer.
